Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
about
Silymarin for HCV infectionDifferential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailabilityTwo flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrationsEvaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytesSilybin and the liver: from basic research to clinical practice."Silymarin", a promising pharmacological agent for treatment of diseasesThe Chemical Biology of Molecular Chaperones--Implications for Modulation of ProteostasisSilybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.Hepatoprotective effect of the solvent extracts of Viola canescens Wall. ex. Roxb. against CCl4 induced toxicity through antioxidant and membrane stabilizing activity.Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Inhibitory effects of flavonoids on molybdenum hydroxylases activity.Effects of herbal products on the metabolism and transport of anticancer agents.Herb-drug pharmacokinetic interactions reviewed.Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease.Theranostics meets traditional Chinese medicine: rational prediction of drug-herb interactions.The therapeutic potential of milk thistle in diabetes.The potential of flavonoids in the treatment of non-alcoholic fatty liver disease.Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept.New insights into the effects of formulation type and compositional mixtures on the antioxidant and cytotoxic activities of dietary supplements based-on hepatoprotective plants.Anti-fibrotic effects of Cuscuta chinensis with in vitro hepatic stellate cells and a thioacetamide-induced experimental rat model.Cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin.Self-nanoemulsifying drug delivery systems ameliorate the oral delivery of silymarin in rats with Roux-en-Y gastric bypass surgeryEffect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes.Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits.Protective effects of Ampelopsis brevipedunculata against in vitro hepatic stellate cells system and thioacetamide-induced liver fibrosis rat model.In-vitro stability and metabolism of a tacrine-silibinin codrug.Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Inhibitory effects of cedrol, β-cedrene, and thujopsene on cytochrome P450 enzyme activities in human liver microsomes.Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomesEvaluation of DA-9801, a new herbal drug for diabetic neuropathy, on metabolism-mediated interactionEnhancement of Silymarin Anti-fibrotic Effects by Complexation With Hydroxypropyl (HPBCD) and Randomly Methylated (RAMEB) β-Cyclodextrins in a Mouse Model of Liver Fibrosis
P2860
Q26851453-3AAC2F2A-05D9-42FA-9231-A52CEF78F482Q30997889-46E46BDB-4298-455E-8F51-DC2E9415753CQ33649076-60B85700-733D-415D-AE99-D54D29A336B8Q33713924-D1D7D5CF-C161-4F47-ABDE-A923D8C00F9AQ33714834-1EC0CC59-12FD-4CAD-A4B0-71FFC335F834Q34469619-118F235A-EE83-4529-8D2D-376D1CF4B77AQ34470980-93CEB2CD-D72B-4880-AAB1-394A64B238E7Q34629765-E2B43D2B-10CC-49FE-8A41-2F6C417487CAQ34649335-6E21BB8B-00AE-4275-A462-05FA44A02F55Q36059002-B1D93687-F2FB-40DE-A618-DC041ACE895DQ36192046-0FE22F63-AC2B-47E6-8F8F-9FD9E80A8C15Q36241263-C1108559-4AE0-4AC9-9A6F-1C0DA8EDE3EAQ36776621-E6E5E726-266D-43A9-BE2C-42E35EC0F3A3Q37679897-391C875C-C80C-4F39-A80B-427DB4C993A1Q37779320-A2E40797-EB35-446C-9C83-DEE26C65417CQ37808478-1B024E62-C8F0-4D27-A285-9D50FEC1B914Q38058825-0CA6F37E-D14C-4184-A745-A679695FA61DQ38068221-07F078D7-7BA3-42ED-A3FB-1CFF2E2F7206Q38268147-C1946A70-C331-431F-9ADD-A0A35C188876Q38432731-9AF1E87C-B643-4AEF-AB19-27C839ECFD34Q38736761-8F8AA35B-57E6-4119-AF10-12E337257DF5Q38969012-BA98D0CA-B055-4788-AA13-B09E9BA84C62Q40157665-11A16E21-B7BE-4358-96DB-F3F79DBED014Q40547961-2BF0E361-5CB1-4DB5-9779-131217EC4DF0Q41969540-D7B39CE1-267C-4E46-958B-97D954F13476Q43605126-D017A427-D92E-4525-A889-C0BD964ED606Q44281046-23EA9721-5F91-450C-9AA4-9B7F5C29A687Q46386681-E84E2333-E77A-452E-80C1-1A7DACCFD2FEQ46986336-62A553FE-4ED3-4FBD-B514-A03D244F5507Q47640131-FD6DCB4D-FB34-4F4D-BEE8-D4A6CE5E4376Q48246851-066A2CE4-4E05-4783-9D2B-C6FB72DAC1F3Q55058629-470D2EAE-772C-43A7-9A4E-88E77643FB89Q57221538-18F10899-C70B-4A53-BD88-279D087F48DFQ57224427-CAF581A9-70BD-4480-BE7B-0DD2302152F3Q58785915-F9E4E8B2-9DA6-4162-B6C7-B5D38500AA4E
P2860
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@ast
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@en
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@nl
type
label
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@ast
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@en
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@nl
prefLabel
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@ast
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@en
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@nl
P2093
P1476
Drug-drug interactions of silymarin on the perspective of pharmacokinetics.
@en
P2093
Jhy-Wen Wu
Lie-Chwen Lin
Tung-Hu Tsai
P304
P356
10.1016/J.JEP.2008.10.036
P577
2008-11-08T00:00:00Z